Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-masked, Active Controlled Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops 0.05% in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients

NCT06212973 is registered in ClinicalTrials.gov with Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. as lead sponsor.

NCT NCT06212973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06212973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-masked, Active Controlled Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops 0.05% in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients
Lead sponsor
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 13, 2023
Completion date
November 2, 2023
Enrollment
266 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic conjunctivitis